000087554 001__ 87554 000087554 005__ 20200716101524.0 000087554 0247_ $$2doi$$a10.1016/j.arbres.2018.12.002 000087554 0248_ $$2sideral$$a110675 000087554 037__ $$aART-2019-110675 000087554 041__ $$aspa 000087554 100__ $$aCabrera López, C. 000087554 245__ $$aValidación pronóstica según los criterios de la GesEPOC 2017 000087554 260__ $$c2019 000087554 5060_ $$aAccess copy available to the general public$$fUnrestricted 000087554 5203_ $$aIntroduction: The Spanish COPD guidelines (GesEPOC) have been recently modified. The aim of this study is to assess this revision and evaluate the prognosis of patients according to the new classification of severity. Methods: A total of 700 COPD patients (83.9% men) were prospectively followed up for a mean period of 5 years in tertiary hospitals in Spain and the USA. Anthropometric data, lung function tests, dyspnea (according to the mMRC scale), BODE and Charlson index were collected. We calculated mortality at 5 years following the risk criteria proposed by the new GesEPOC. Results: Mean age was 66 ± 9.6 years and mean FEV1% was 59.7 ± 20.2. The proportion of patients in the low-risk group was 40.43%. Patients in the high-risk group had a significantly higher BODE index than those in the low-risk group (2.92 ± 0, 66 vs. 0.52 ± 1.91, p < 0.001), while the Charlson index score was similar in both groups. Mortality at 60 months was significantly higher in the high-risk group (31.7% vs. 15.5%, p < 0.001). Dyspnea and FEV1% were also independent predictors of mortality (p < 0.001), and neither was inferior to the risk classification proposed by GesEPOC. Conclusions: The new severity index proposed by GesEPOC accurately predicts 5-year mortality. However, dyspnea and FEV1% have the same strength in predicting mortality. 000087554 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000087554 590__ $$a4.957$$b2019 000087554 591__ $$aRESPIRATORY SYSTEM$$b11 / 64 = 0.172$$c2019$$dQ1$$eT1 000087554 592__ $$a0.287$$b2019 000087554 593__ $$aPulmonary and Respiratory Medicine$$c2019$$dQ3 000087554 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000087554 700__ $$aCasanova Macario, C. 000087554 700__ $$0(orcid)0000-0001-9096-2294$$aMarín Trigo, J.M.$$uUniversidad de Zaragoza 000087554 700__ $$ade-Torres, J.P. 000087554 700__ $$aTorres, R.S. 000087554 700__ $$aGonzález, J.M. 000087554 700__ $$aPolverino, F. 000087554 700__ $$aDivo, M. 000087554 700__ $$aPinto Plata, V. 000087554 700__ $$aZulueta, J. 000087554 700__ $$aCallejas, F.J. 000087554 700__ $$aCelli, B. 000087554 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000087554 773__ $$g55, 8 (2019), 409-413$$pArch. bronconeumol.$$tArchivos de Bronconeumologia$$x0300-2896 000087554 8564_ $$s461018$$uhttps://zaguan.unizar.es/record/87554/files/texto_completo.pdf$$yPostprint 000087554 8564_ $$s17489$$uhttps://zaguan.unizar.es/record/87554/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000087554 909CO $$ooai:zaguan.unizar.es:87554$$particulos$$pdriver 000087554 951__ $$a2020-07-16-09:29:07 000087554 980__ $$aARTICLE